Alogliptin

Alogliptin
	File:Alogliptin.svg
Clinical data
Routes of; administration	Oral
Identifiers
	IUPAC name 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-; 3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile;
CAS Number	850649-62-6;
PubChem CID	11450633;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C18H21N5O2
Molar mass	339.39 g/mol
3D model (JSmol)	Interactive image;
	SMILES N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC[C@@H](N)C2;

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Alogliptin (codenamed SYR-322) is an investigational anti-diabetic drug in the DPP-4 inhibitor class,^[1] being developed by Takeda Pharmaceutical Company. Takeda has submitted a New Drug Application for alogliptin to the U.S. Food and Drug Administration, after positive results from Phase III clinical trials.^[2]

References

↑ Feng J, Zhang Z, Wallace MB; et al. (2007). "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". J. Med. Chem. 50 (10): 2297–300. doi:10.1021/jm070104l. PMID 17441705.
↑ "Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S." (Press release). Takeda Pharmaceutical Company. January 4 2008. Retrieved 2008-01-09. Check date values in: |date= (help)

Template:Pharma-stub Template:Oral hypoglycemics

Template:WH Template:WS

[pmid17441705-1] Feng J, Zhang Z, Wallace MB; et al. (2007). "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". J. Med. Chem. 50 (10): 2297–300. doi:10.1021/jm070104l. PMID 17441705.

[2] "Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S." (Press release). Takeda Pharmaceutical Company. January 4 2008. Retrieved 2008-01-09. Check date values in: |date= (help)

[1]

[2]

Clinical data
File:Alogliptin.svg
Routes of administration	Oral
Identifiers
IUPAC name 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo- 3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
CAS Number	850649-62-6
PubChem CID	11450633
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₈H₂₁N₅O₂
Molar mass	339.39 g/mol
3D model (JSmol)	Interactive image
SMILES N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC[C@@H](N)C2

Alogliptin

References

Navigation menu